| Literature DB >> 29439698 |
Tobias Schmidt1,2, Katharina Ebert3, Tim Rolvien3,4, Nicola Oehler4, Jens Lohmann5, Luca Papavero5, Ralph Kothe5, Michael Amling3, Florian Barvencik3, Haider Mussawy3,4.
Abstract
BACKGROUND: Impaired bone quality is associated with poor outcome of spinal surgery. The aim of the study was to assess the bone mineral status of patients scheduled to undergo spinal surgery and to report frequencies of bone mineral disorders.Entities:
Keywords: Anti-osteoporotic medication; Hypochlorhydria; Osteoporosis; Secondary hyperparathyroidism; Vitamin D deficiency
Mesh:
Year: 2018 PMID: 29439698 PMCID: PMC5811985 DOI: 10.1186/s12891-018-1970-5
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1a Sample images of lateral vertebral fracture assessment by DXA in patients without vertebral fracture; b with moderate deformity of the first and second lumbar vertebrae; c and with severe deformity of the second lumbar vertebra and moderate deformity of the twelfth thoracic vertebra. d Sample image of the peripheral quantitative computed tomographic analysis of the distal radius and distal tibia of a patient with severe vertebral deformity. Note that the same patient exhibits a strong decrease in the trabecular compartment at the distal radius and a less pronounced decrease in trabecular variables at the distal tibia. Values are normalized to age-, site-, and sex-specific reference values. Abbreviations: HR-pQCT, peripheral quantitative computed tomography; Tt.BMD, total volumetric bone mineral density. Tb.N; trabecular numbers Tb.Sp; trabecular separation Tb.Th; trabecular thickness
Demographic and laboratory data of of patients requiring spinal surgery
| Mean (± SD) or n (%) | |
|---|---|
| n | 144 |
| Sex (no. of female, %) | 96 (66.4) |
| Mean age in yr | 70.1 (8.1) |
| Age (no. of patients) | |
| 50–60 yr | 18 (12.5%) |
| 60–70 yr | 55 (38.2%) |
| > 70 yr | 71 (49.3%) |
| Weight (kg) | 74.8 (14.4) |
| Height (cm) | 168.0 (9.4) |
| Height change (cm) | 3.7 (2.9) |
| Mean BMI (± SD) | 26.2 (4.7) |
| History of a vertebral fracture | 42 (29.1%) |
| Unknown vertebral deformity (Diagnosed by VFA) | 12 (8.3%) |
| Proton pump inhibitor use | 44 (30.6%) |
| Laboratory values | |
| 25-OH-D (ng/ml) | 24.3 (11.8) |
| Parathyroid hormone (ng/l) | 84.3 (47.1) |
| Calcium (mmol/l) | 2.23 (0.1) |
| Bone specific AP (μg/l) ( | 13.6 (7.9) |
| Osteocalcin (μg/l) ( | 18.9 (11.8) |
| Urine DPD ( | 6.7 (2.8) |
| Elevated DPD | 74 (69.2%) |
| Elevated Gastrin | 20 (13.9%) |
T-scores and Z-scores of the DXA measurements in patients with different indication for spinal surgery (mean ± SD)
| n | T-Score lumbar spine | Z-Score lumbar spine | T-Score femoral neck | Z-Score femoral neck | |
|---|---|---|---|---|---|
| All patients | 144 | −1.23 (1.4) | - 0.1 (1.5) | - 1.4 (1.0) | - 0.08 (1.1) |
| Indication for spinal surgery | |||||
| Lumbar spinal stenosis | 70 | −1.29 (1.73) | 0.07 (1.56) | −1.62(1.15) | −0.04 (1.08) |
| Degenerative spondylolisthesis | 35 | −1.14 (1.45) | − 0.20 (1.38) | − 1.16 (0.98) | 0.12 (1.10) |
| Herniation of lumbar disc | 31 | −0.77 (1.21) | −0.04 (1.41) | −1.06 (0.88) | 0.32 (1.38) |
| Compression fracture | 8 | −2.6 (1.3) | −1.27 (0.91) | −1.72 (1.07) | −0.13 (1.05) |
Differences in bone microarchitecture between the patients with moderate/severe vertebral deformity and the patients without vertebral fractures
| No Deformity | Moderate Deformity | Severe Deformity | |||
|---|---|---|---|---|---|
| n | 34 | 21 | 12 | ||
| Mean age, years | 71 | 71.9 | 72 | ||
| HR-pQCT variables | |||||
| Radius (normalized to age- and sex-specific reference values) | % | % | Δ % | % | Δ % |
| Total bone area | 109.8 (15.7) | 113.4 (18.5) | + 3.5 | 110.2 (30.7) | + 0.35 |
| Cortical area | 88.8 (21.7) | 78.3 (27.3) | −10.5 | 65.4 (19.5) | − |
| Trabecular area | 110.8 (20.4) | 117.2 (24.4) | + 6.2 | 116.7 (36.8) | + 5.7 |
| Total vBMD | 94.9 (20.7) | 87.2 (18.9) | −7.6 | 76.2 (12.5) | − |
| Cortical vBMD | 83.3 (7.0) | 80.1 (8.4) | −3.1 | 77.7 (6.9) | −5.5 |
| Trabecular vBMD | 100.7 (20.7) | 93.5 (25.7) | −7.3 | 79.7 (17.4) | − |
| Cortical thickness | 70.4 (18.9) | 61.1 (24.4) | −9.4 | 50.8 (14.9) | − |
| Trabecular numbers | 106.8 (14.6) | 102.4 (22.7) | −4.4 | 92.4 (16.9) | − |
| Trabecular thickness | 94.9 (13.1) | 92.0 (17.3) | −2.8 | 87.1 (13.5) | − |
| Trabecular separation | 95.8 (15.8) | 105.3 (32.2) | + 9.5 | 116.8 (28.1) | + |
| Tibia (normalized to age- and sex-specific reference values) | % | % | Δ % | % | Δ % |
| Total bone area | 112.1 (17.5) | 115.5 (21.3) | + 3.4 | 109.8 (19.5) | −2.3 |
| Cortical area | 90.7 (15.2) | 91.6 (18.5) | + 0.9 | 81.7 (15.7) | −9.0 |
| Trabecular area | 98.3 (15.4) | 99.4 (22.6) | + 1.1 | 95.6 (20.7) | −2.6 |
| Total vBMD | 90.7 (15.2) | 91.6 (18.4) | + 0.9 | 81.7 (15.7) | −9.0 |
| Cortical vBMD | 85.8 (8.8) | 86.4 (8.9) | + 0.6 | 82.7 (7.9) | −3.1 |
| Trabecular vBMD | 98.5 (18.9) | 98.5 (23.6) | −0.0 | 87.8 (18.2) | −10.6 |
| Cortical thickness | 67.7 (21.5) | 68.9 (26.0) | + 1.2 | 58.8 (23.8) | −8.8 |
| Trabecular numbers | 110.1 (18.5) | 105.8 (25.4) | −4.3 | 102.9 (22.1) | −7.1 |
| Trabecular thickness | 90.6 (15.7) | 93.2 (12.4) | + 2.6 | 87.0 (19.1) | −3.6 |
| Trabecular separation | 94.1 (19.6) | 101.5 (29.6) | + 7.4 | 104.9 (28.9) | + 10.8 |
Abbreviations: HR-pQCT, peripheral quantitative computed tomography; vBMD, volumetric bone mineral density
The data are normalized to age- and sex-specific reference values. The differences (∆) that are shown are relative to the non-fracture group.
* = Statistically significant (p < 0.05) differences to the non-fracture group
Fig. 2a Prevalence of 25-OH-D deficiency and secondary hyperparathyroidism in 144 patients scheduled for spine surgery. b Levels of 25-OH-D (ng/ml) and parathyroid hormone (ng/l) in patients in dependence of daily vitamin D intake. * p < 0.05
Anti-osteoporotic treatment in patients undergoing spinal surgery prior and recommendation after evaluation of bone mineral status
| Prior to Evaluation | Recommendation | |
|---|---|---|
| n (%) | n (%) | |
| Basic therapy | ||
| Vitamin D supplementation | 57 (39.6%) | 144 (100%) |
| Adequate vitamin D supplementation (25-OH-D within recommended range) | 28 (19.4%) | |
| Calcium supplementation | 31 (21.5%) | 20 (13.9%) |
| Specific anti-osteoporotic treatment | 16 (11.1%) | 70 (48.6%) |
| Bisphosphonate (oral) | 8 (5.6%) | 26 (18%) |
| Bisphosphonate (intravenous) | 0 (0%) | 14 (9.7%) |
| Denosumab | 8 (5.6%) | 25 (17.3%) |
| Teriparatide | 0 (0%) | 5 (3.5%) |
| Indication for specific treatment without therapy | 54 (37.5%) | |
Fig. 3Flow chart of bone mineral status in 144 patients scheduled for spine surgery and recommendation for medical treatment